Impact of RAS mutations on the immune infiltrate of colorectal liver metastases: A preliminary study
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Leukocyte Biology"
DOI: 10.1002/jlb.5ab0220-608r
Abstract: Kirsten rat sarcoma viral oncogene homolog KRAS proto‐oncogene is the most common altered gene in colorectal cancer (CRC). Determining its mutational status, which is associated with worse prognosis and resistance to anti‐epidermal growth factor receptor… read more here.
Keywords: liver metastases; kras mutated; ras mutations; study ... See more keywords
A large scale proteome analysis of the gefitinib primary resistance overcome by KDAC inhibition in KRAS mutated adenocarcinoma cells overexpressing amphiregulin.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of proteomics"
DOI: 10.1016/j.jprot.2019.01.009
Abstract: KDAC inhibitors (KDACi) overcome gefitinib primary resistance in non-small cell lung cancer (NSCLC) including mutant-KRAS lung adenocarcinoma. To identify which proteins are involved in the restoration of this sensitivity and to provide new therapeutic targets… read more here.
Keywords: kras mutated; gefitinib; kdac; primary resistance ... See more keywords
Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2024 at "British Journal of Cancer"
DOI: 10.1038/s41416-024-02727-2
Abstract: Recent therapeutic strategies for KRAS-mutated cancers that inhibit the MAPK pathway have attracted considerable attention. The RAF/MEK clamp avutometinib (VS-6766/CH5126766/RO5126766/CKI27) is promising for patients with KRAS-mutated cancers. Although avutometinib monotherapy has shown clinical activity in… read more here.
Keywords: combination; cancer; avutometinib defactinib; kras mutated ... See more keywords
Extensive genomic analysis in patients with KRAS-mutated solid tumors shows high frequencies of concurrent alterations and potential targets but has limited clinical impact
Sign Up to like & getrecommendations! Published in 2022 at "Acta Oncologica"
DOI: 10.1080/0284186x.2022.2156809
Abstract: Abstract Background This study aimed to investigate the distribution and frequency of concurrent alterations in different cancers across KRAS subtypes and in different KRAS subtypes across cancers, and to identify potentially actionable targets and patients… read more here.
Keywords: genomic analysis; analysis patients; kras mutated; extensive genomic ... See more keywords
Heterogeneous alteration of the ERBB3–MYC axis associated with MEK inhibitor resistance in a KRAS-mutated low-grade serous ovarian cancer patient
Sign Up to like & getrecommendations! Published in 2019 at "Cold Spring Harbor Molecular Case Studies"
DOI: 10.1101/mcs.a004341
Abstract: Low-grade serous ovarian cancer (LGSOC) is relatively chemoresistant, and no precision therapy is approved for this indication. Despite promising results in phase II trials, MEK inhibitors have failed to show improved progression-free survival in a… read more here.
Keywords: kras mutated; inhibitor; mek inhibitor; inhibitor resistance ... See more keywords
Quadruple‐editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS‐mutated colorectal cancer cells
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Science"
DOI: 10.1111/cas.15049
Abstract: Mutated KRAS promotes the activation of the MAPK pathway and the progression of colorectal cancer (CRC) cells. Aberrant activation of the PI3K pathway strongly attenuates the efficacy of MAPK suppression in KRAS‐mutated CRC. The development… read more here.
Keywords: kras mutated; crc cells; quadruple editing; mapk pi3k ... See more keywords
Genotype‐guided targeted treatment of KRAS‐mutated arteriovenous malformations
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.18165
Abstract: 1966; 34: 827–857 PMID:5330347. 7 Insee. A Mayotte, pr es d’un habitant sur deux est de nationalit e etrang ere. Montrouge, Paris: Insee Premi ere. 2019;1737 [Internet]. French. https:// www.insee.fr/fr/statistiques/3713016 (last accessed 16 November 2021).… read more here.
Keywords: genotype guided; targeted treatment; kras mutated; guided targeted ... See more keywords
Dysregulation of NK and CD8+T Cells by the Microbiota Promotes the Progression of Lung Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Immunology Research"
DOI: 10.1155/2022/7057089
Abstract: The commensal microbiota is involved in maintaining local pulmonary immune homeostasis under physiological conditions. Alterations in the amount and dominant species of the microbiota can reshape the immune response of the body and lead to… read more here.
Keywords: progression lung; lung cancer; lung; kras mutated ... See more keywords
Abstract C045: Exploring EGLN1/PHD2 role in KRAS mutated lung cancer: insights into mitochondrial modulation and therapeutic opportunities
Sign Up to like & getrecommendations! Published in 2025 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-25-c045
Abstract: Lung cancer is the first cause of cancer-related death. In lung adenocarcinoma (LUAD), different genetic alterations can be targeted with small-molecule compounds, including the KRAS inhibitors. However, the development of resistance mechanisms indicates that exploring… read more here.
Keywords: cancer; kras mutated; role; lung cancer ... See more keywords
Abstract 2916: Protein arginine methyltransferase 5 as a therapeutic target for KRAS mutated colorectal cancer
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-2916
Abstract: Introduction Protein Arginine Methyl Transferase 5 (PRMT5) is a transcription regulator for multiple cellular processes. It is being tested as a potential target/biomarker in several cancer types. Herein we analyzed the therapeutic efficacy of PRMT5… read more here.
Keywords: kras mutated; colorectal cancer; protein arginine; crc ... See more keywords
Abstract CT235: A phase 1b/2 study of onvansertib (PCM-075) in combination with FOLFIRI and bevacizumab for second line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC)
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-ct235
Abstract: Background: Chemotherapy in combination with targeted agents are standard-of-care options for patients for mCRC with response rates >50% in first line. In the second line setting, efficacy of chemotherapy and targeted agents are much lower… read more here.
Keywords: kras mutated; phase; folfiri bevacizumab; line ... See more keywords